Optimi Health

Optimi Health EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Optimi Health (OPTI.CN) as of Nov 3, 2026 is -30.32 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -38.55 % — a change of -21.35% (higher).

EBIT/Assets

-30.32 %

YoY

-21.35%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Optimi Health is 2025 -30.32 % . Operating Income to Assets Ratio (EBIT/Assets) of Optimi Health was 2024 -38.55 % . It decreases by -21.35% higher compared to the previous year.

The Optimi Health EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2021
-25.81 CAD
Jan 1, 2022
-43.94 CAD
Jan 1, 2023
-31.97 CAD
Jan 1, 2024
-38.55 CAD
Jan 1, 2025
-30.32 CAD
The Optimi Health EBIT/Assets history
YEAREBIT/AssetsYoY
-30.32 %-21.35%
-38.55 %+20.58%
-31.97 %-27.24%
-43.94 %+70.26%
-25.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Optimi Health Stock analysis

What does Optimi Health do? Optimi Health Corp develops, cultivates, extracts, processes, and distributes functional mushrooms and psychedelic substances. The company produces licensed drug and nutraceutical products including natural and synthetically formulated GMP-grade psilocybin, psilocin, MDMA, and other psychedelic substances under Health Canada regulations. Optimi supplies health food distributors, drug developers, and patients through its manufacturing facilities. The firm operates as a supplier of drug and nutraceutical products serving domestic and international health and wellness markets. Optimi Health Corp owns approximately 20,000 technologically advanced manufacturing, cultivation, and analytical facilities. These facilities support the production of functional mushrooms and psychedelic substances for health food distributors, drug developers, and patients. The company focuses on supplying synthetic and natural psychedelics to the international market while adhering to Health Canada's drug manufacturing and formulation standards. The firm's product portfolio includes GMP-grade psilocybin, psilocin, MDMA, and functional mushrooms, targeting health food distributors, drug developers, and patients. Optimi operates as a supplier of drug and nutraceutical products, serving both domestic and international health and wellness markets. Its manufacturing capabilities enable the production of natural and synthetically formulated psychedelic substances under Health Canada's regulatory framework. Optimi Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Optimi Health stock

Operating Income to Assets Ratio (EBIT/Assets) of Optimi Health is -30.32 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Optimi Health changed from -38.55 % to -30.32 %, representing a -21.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Optimi Health since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Optimi Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Optimi Health

All Key Metrics — Optimi Health